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Abstract.	
Alcohol intoxication is the third leading cause of death, and among alcohol-
dependent patients alcohol-related pathology (alcoholic liver disease, acute and 
chronic pancreatitis, cardiomyopathy, polyneuro-encephalopathy) accounts for 42.6% 
of fatal cases. In many cases prominent feature of liver damage can be detected in 
people who consume alcohol in moderation and they can hardly be called alcoholics. 
The objective of the research was to study the long-term results of the 
effectiveness of treating patients with chronic alcoholic pancreatitis and concomitant 
alcoholic liver cirrhosis Child-Pugh Class A and B as well as to establish prognostically 
unfavorable parameters of the clinical course of the comorbidity.  
Materials and methods. The study included 89 patients with alcohol-related 
pathology who were observed prospectively for 1 year. 50 patients suffered from 
chronic alcoholic pancreatitis and concomitant liver cirrhosis Child-Pugh Class A and 
B; 20 patients were diagnosed with alcoholic liver cirrhosis without damage to the 
pancreas; 19 patients developed chronic alcoholic pancreatitis. Patients with liver 
cirrhosis received therapy according to the Order of the Ministry of Health of Ukraine of 
06.11.2014, No 826 “Unified clinical protocol of primary, secondary (specialized) 
medical care “Alcoholic hepatitis”; patients with chronic alcoholic pancreatitis 
received therapy according to the Order of the Ministry of Health of Ukraine of 
10.09.2014, No 638 “On approval and implementation of medical and technical 
documents on standardization of medical care in chronic pancreatitis”. Patients with 
chronic alcoholic pancreatitis and concomitant liver cirrhosis Child-Pugh Class A and 
B were divided into 2 subgroups. Subgroup I (20 patients) received combination therapy 
according to the Orders of the Ministry of Health of Ukraine mentioned above. 
Subgroup II (30 patients) received pentoxifylline (Pentoxifylline-Darnitsa) at a dose of 
5 ml of 2% solution per 200 ml of 0.9% sodium chloride solution intravenously for 5 
days with further transition to oral medications at a dose of 200 mg up to two months 
including the mixture of essential, conditionally essential and non-essential amino 
acids (Hepasol-Neo) at a dose of 500 ml of 8% solution intravenously on alternate days 
5 times in addition to basic therapy. 
Conclusions. Concurrent alcohol-induced injury of the pancreas and liver increases 
the risk of developing more severe clinical course of this comorbidity with transition 
of cirrhosis to the decompensated stage, bleeding varicose veins in the esophagus 
occurring more often, increased pancreatic fibrosis with widening of the ductal system 
and further development of cysts and pancreatic exocrine insufficiency. The addition 
of pentoxifylline and mixture of essential, conditionally essential and non-essential 
amino acids to basic therapy reduces the number of patients developing 
complications. 
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Problem statement and analysis of the recent research 
Alcohol abuse often results in systemic multiple organ lesions involving the liver and 
pancreatic gland (PG) manifested themselves as acute and chronic conditions [5]. According to the 
author, alcohol intoxication is the third leading cause of death, and among alcohol-dependent 
patients alcohol-related pathology (alcoholic liver disease, acute and chronic pancreatitis, 
cardiomyopathy, polyneuro-encephalopathy) accounts for 42.6% of fatal cases. According to other 
authors, alcoholism is killing 2.5 million people every year worldwide accounting for 4% of overall 
mortality and the main cause of this phenomenon is alcoholic hepatitis and liver cirrhosis of different 
severity degrees [18]. Both the liver and PG is the primary target of the toxic effect of alcohol in its 
excessive consumption that is explained by systemic nature of its metabolism, common mechanisms 
of neuroregulation of the digestive system functions, uniformity of the influence, the 
interdependence of the liver and PG in the process of digestion [2, 3]. This problem is also relevant 
due to the fact that in many cases prominent feature of liver damage can be detected in people who 
consume alcohol in moderation and they can hardly be called alcoholics [8]. The medical and social 
significance of digestive problems caused by alcohol abuse is also evidenced by the fact that they 
rank second among causes of liver transplantation in Europe [15]. 
In its early stages chronic alcoholic pancreatitis (CAP) may be accompanied by complications 
similar to those in acute alcoholic pancreatitis including necrotizing pancreatitis, pseudocyst 
formation, exocrine and endocrine insufficiency, visceral artery 
aneurysms and pseudoaneurysms, etc. [20]. Alcohol also plays a significant role in the development 
of calcifying pancreatitis [4]. 
The prognosis for patients with CAP under conditions of further abstinence depends on their 
adherence to the doctor’s recommendations as well as keeping to a strict diet, and adequacy of 
maintenance treatment. 70-80% of patients who adhere to the instructions mentioned above live for 
about 10 years and in case of noncompliance 50% of patients die sooner [11]. 
Due to the improvement of therapy for alcoholic liver disease (ALD), cirrhosis and its 
complications in particular, the prognosis for the disease has improved recently. It depends under 
condition of total abstinence on the functional state of the liver, complications. In decompensated 
liver cirrhosis (LC) (Child-Pugh Class C) only 11-14% of patients are alive 3 years after diagnosis and 
in case of developing complications such as ascites life expectancy does not exceed 2–3 years. 
According to the data of Shipulin VP, et al [10] 12 out of 59 patients with Child-Pugh Class B and C 
cirrhosis being under observation died 1 year after therapy including essential phospholipids and 
lipoic acid; two years after the beginning of the observation 71% out of 59 patients were alive. 
Taking into consideration the above-mentioned data the problem of predicting the 
effectiveness of therapy for alcohol-related injuries of the liver remains relevant. Particularly, 
Rachkovskyi MI [6] suggested several models of predicting survival in patients with alcoholic LC after 
treatment: the first model determines aspartate aminotransferase activity and serum creatinine 
levels and second one is based on estimating the time for maximum accumulation of 99Tc-bromide 
in the liver according to the data of dynamic hepatobiliary scintigraphy which is not readily available 
in clinical practice. Abrahamovych OO, et al [11] recommend to use the parameters of ultrasound 
Doppler flowmetry of the portal venous system in order to predict the effectiveness of therapy for 
LC. More available and simpler criteria based on the overall estimation of changes in parameters 
such as the level of bilirubin, ALAT, ASAT, thymol sample, superoxide dismutase activity, malonic 
aldehyde level, tumor necrosis factor, interleukin-4, type IV collagen, leptin, medium molecular 
peptides were proposed by Samohalska OE, et al [7]. There are also other criteria, the MELD score in 
particular:  a value of more than 32 indicates a high mortality within a relatively short period serving 
as an indication for the administration of glucocorticoids [18]. The GAHS, ABIC and Lille Model Score 
can be also used to predict the outcomes of ALD. The latter model including the patient’s age, degree 
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of kidney failure (creatinine clearance<40), international normalized ratio>1.3, albumin level, 
prothrombin time (PT), bilirubin allows us to predict a 6-month survival. Therefore, as indicated by 
the analysis of the above-mentioned data, the problem of predicting the effectiveness of therapy for 
both CAP and alcoholic LC requires further improvement.  
The objective of the research was to study the long-term results of the effectiveness of 
treating patients with CAP and concomitant alcoholic LC Child-Pugh Class A and B as well as to 
establish prognostically unfavorable parameters of the clinical course of the comorbidity.  
 
Materials and methods 
The study included 89 patients with alcohol-related pathology who were observed 
prospectively for 1 year. Alcoholic genesis of injury of the liver and PG was confirmed by the patient’s 
life history, past medical history, particularly observation by therapists for alcoholics or drug abusers, 
the MAST and the CAGE Questionnaire,  the Le Go Grid method, objective stigmata of alcoholism. 50 
patients suffered from chronic alcoholic pancreatitis and concomitant liver cirrhosis Child-Pugh 
Class A and B; 20 patients were diagnosed with alcoholic liver cirrhosis without damage to the 
pancreas; 19 patients developed chronic alcoholic pancreatitis. Patients with liver cirrhosis received 
therapy according to the Order of the Ministry of Health of Ukraine of 06.11.2014, No 826 “Unified 
clinical protocol of primary, secondary (specialized) medical care “Alcoholic hepatitis”; patients with 
chronic alcoholic pancreatitis received therapy according to the Order of the Ministry of Health of 
Ukraine of 10.09.2014, No 638 “On approval and implementation of medical and technical documents 
on standardization of medical care in chronic pancreatitis”. Patients with chronic alcoholic 
pancreatitis and concomitant liver cirrhosis Child-Pugh Class A and B were divided into 2 subgroups. 
Subgroup I (20 patients) received combination therapy according to the Orders of the Ministry of 
Health of Ukraine mentioned above. Subgroup II (30 patients) received pentoxifylline (Pentoxifylline-
Darnitsa) at a dose of 5 ml of 2% solution per 200 ml of 0.9% sodium chloride solution intravenously 
for 5 days with further transition to oral medications at a dose of 200 mg up to two months including 
the mixture of essential, conditionally essential and non-essential amino acids (Hepasol-Neo) at a 
dose of 500 ml of 8% solution intravenously on alternate days 5 times in addition to basic therapy. 
To assess the prediction and long-term results of treatment the odds ratio (OR) and 
the 95% confidence interval (CI) were used. The survival in patients of the main group suffering from 
CAP and concomitant LC Child-Pugh Class A and B was analyzed by the Kaplan-Meier method. The 
cumulative proportion surviving (%) in patients was calculated during different observation periods. 
The transition of LC Child-Pugh Class A and B to LC Child-Pugh Class C, bleeding from varicose 
veins in the esophagus, development of pancreatic cysts, death served as study endpoints.  
 
Results and discussion 
The odds ratios for transition of LC Child-Pugh Class A and B to LC Child-Pugh Class C after 
basic therapy were analyzed. The odds ratio was the most probable in case of serum albumin level 
of below 35% (OR–28.50, р<0.001), higher than normal levels of total bilirubin, reduced serum 
cholinesterase levels, increased serum concentration of type IV collagen >300 pg/ml, acceleration of 
wave velocity according to the results of liver elastography >2.64 m/s with a probability of 15.5; 19.0 
and 44.3 times (Table 1, Fig.1). 
 
Table 1 
Odds ratio in patients with alcoholic LC Child-Pugh Class A and B 
Parameter OR 95% CI р Хі2 
Total bilirubin, >20.5 mmol/l 35.29 3.87-321.83 0.00027 13.30 
Albumins, <35%  28.50 3.16-257.44 0.00074 11.40 
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PT, <60%  10.36 1.10-97.69 0.05441 3.70 
Ascites 6.33 0.67-60.16 0.18404 1.76 
Type IV collagen, >300 pg/ml 19.00 2.12-170.38 0.00461 8.03 
Elastometry, >2.64 m/s 44.33 4.78-410.94 0.0009 15.36 
Phospholipase A2 type IIA, >200 pg/ml 13.57 1.34-137.45 0.03530 4.43 
Cholinesterase, <5000 15.55 1.73-139.65 0.01059 6.53 
Notes: OR – odd ratio; 95% CI - confidence interval; p - probability criterion 
 
 
Fig. 1. Relative risk of complications in patients with LC Child-Pugh Class A and B 
 
Correlation between increased chances of developing complications and mortality in 
alcoholic LC and decreased albumin level as wells as the development of hepatic encephalopathy 
and duration of alcohol consumption is indicated by other researches as well [12]. 
Unfavorable prognostic factors for alcoholic LC are known to be divided into exogenous and 
endogenous. Exogenous factors include the quantity and type of alcoholic beverage, duration and 
patterns of alcohol consumption. Endogenous factors include the gender, ethnicity as well as 
comorbid conditions the role of which is proven such as metabolic syndrome, iron overload, infection 
with hepatitis viruses and other conditions including progressive fibrosis [17]. The damage to other 
organs requires clarification [13]. 
In patients with CAP the most unfavorable prognostic indicators of developing complications 
included increased activity of phospholipase A2 type IIA >200 pg/ml and value of fecal chymotrypsin 
activity <6.0 U/g (Table 2, Fig. 2). 
 
Table 2 
Odds ratio in patients with CAP 
Parameter OR 95% CI р Хі2 
Total bilirubin, >20.5 mmol/l 1.36 0.11-16.05 0.71536 0.13 
Albumins, <35%  2.92 0.3-28.29 0.63043 0.23 
PT, <60%  0.66 0.04-11.12 0.65853 0.20 
Type IV collagen, >100 pg/ml 5.78 0.65-51.24 0.18069 1.79 
Chymotrypsin activity, <6 U/g 38.00 3.65-395.21 0.0081 11.22 
Phospholipase A2 type IIA, >200 pg/ml 57.00 5.18-627.14 0.00018 14.00 
Cholinesterase, <5000 4.07 0.8-43.38 0.48177 0.49 
Notes: OR – odd ratio; 95% CI - confidence interval; p - probability criterion 
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Fig. 2. Relative risk of complications in patients with CAP 
 
In patients with CAP and concomitant LC Child-Pugh Class A and B compared to patients with 
CAP only the most unfavorable prognostic parameters included low serum albumin levels, reduced 
prothrombin time ratio, low cholinesterase levels, reduced concentration of type IV collagen (Table 
3, Fig. 3). 
 
Table 3 
Odds ratio in patients with CAP and concomitant LC Child-Pugh Class A and B 
Parameter OR 95% CI р Хі2 
Total bilirubin, >30 mmol/l 60.17 6.60-548.71 0.00001 19.90 
Albumins, <35%  38.00 4.43-326.02 0.00005 16.29 
PT, <60%  12.67 1.40-114.42 0.02310 5.16 
Ascites 8.14 0.88-75.48 0.09601 2.77 
Type IV collagen, >300 pg/ml 40.38 4.57-356.96 0.00007 15.84 
Elastometry, >2.64 m/s 57.00 6.00-514.47 0.00003 17.60 
Phospholipase A2 type IIA, >200 pg/ml 28.50 3.27-248.17 0.00044 12.37 
Cholinesterase, <5000 35.29 3.87-321.93 0.00027 13.30 
Notes: OR – odd ratio; 95% CI - confidence interval; p - probability criterion 
 
 
Fig. 2. Relative risk of complications in patients with CAP and concomitant LC Child-Pugh 
Class A and B 
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The chances of developing adverse events in patients with liver pathology and co-existent 
pancreas pathology exceeded the parameters of the odds ratio compared to patients with alcoholic 
LC only: total bilirubin levels increased by 1.7 times, serum albumin level of below 35% increased by 
1.3 times, serum levels of type IV collagen >300 pg/ml, cholinesterase and phospholipase A2 type IIA 
>200 pg/ml increased by 2.1, 2.1 and 2.2 times, respectively.  
To describe the long-term outcomes in patients with liver pathology and co-existent pancreas 
pathology depending on the method of treatment the Kaplan-Meier method was used. During the 
period of observation 25.0% of patients receiving basic therapy within a year developed the 
progression of liver pathology with the transition to Child-Pugh Class C 4, 5, 6, and 9 months after 
starting treatment. As indicated by Chae HB [16] according to Child-Pugh score more severe clinical 
course largely depends on the levels of total bilirubin and albumin. In patients who received 
pentoxifylline and amino acid mixtures in addition to basic therapy the transition to Child-Pugh Class 
C occurred in 6.7% of cases 9 month after starting treatment (Fig. 4). 
 
 
Variable: Time, months 
Variable with censoring indicator: Transition of LC from Class A and B to Class C  
Grouping variable: Treatment 
Total number of observations: 50 
uncensored: 7 (14.00%)         censored: 43 (86.00%) 
Z = -2.42072                p =  .01549 
Fig. 4. Curves of LC decompensation in patients with comorbid alcohol-related pathology 
depending on treatment scheme  
 
Bleeding varicose veins in the esophagus were observed in 20.0% of patients undergoing basic 
therapy 4, 5, 6, and 9 months after completion of treatment. Among patients who received 
pentoxifylline and Hepasol-Neo in addition to basic therapy such complication was diagnosed in 6.7% 
of patients 5 and 9 months after treatment (Fig. 5). 
The most favorable clinical course of the comorbidity and reduction in the frequency of 
complications in patients receiving pentoxifylline are also indicated by other researchers who 
consider it as an alternative to glucocorticoid treatment [19]. Pancreatic cysts being not diagnosed 
after the completion of treatment were detected in 25% of patients 3, 5, 6, and 9 months after therapy. 
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Variable: Time, months 
Variable with censoring indicator: Bleeding 
Grouping variable: Treatment  
Total number of observations: 50 
uncensored: 6 (12.00%)         censored: 44 (88.00%) 
Z = -1.58740                p =  .11242 
Fig. 5. Curves of bleeding occurrence in patients with comorbid alcohol-related pathology 
depending on treatment scheme  
 
Patients of subgroup II developed only two complications manifested themselves 6 and 8 months 
after completion of treatment (Fig. 6). 30% of patients with liver pathology and co-existent pancreas 
pathology receiving basic therapy and 10% of patients with comorbidity receiving pentoxifylline and 
amino acid mixtures in addition to basic therapy died within a year. 
 
 
Variable: Time, months 
Variable with censoring indicator: Pancreatic cysts formation 
Grouping variable: Treatment  
Total number of observations: 50 
uncensored: 7 (14.00%)         censored: 43(86.00%) 
Z = -2.00731                p =  .04472 
Fig. 6. Curves of pancreatic cysts formation in patients with comorbid alcohol-related 
pathology depending on treatment scheme  
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Conclusions 
Thus, concurrent alcohol-induced injury of the pancreas and liver increases the risk of 
developing more severe clinical course of this comorbidity with transition of LC to 
the decompensated stage, bleeding varicose veins in the esophagus occurring more often, increased 
pancreatic fibrosis with widening of the ductal system and further development of cysts and 
pancreatic exocrine insufficiency. The addition of pentoxifylline and mixture of essential, 
conditionally essential and non-essential amino acids to basic therapy reduces the number of 
patients developing complications.  
 
Prospects for further research include the development of new available schemes to predict 
the effectiveness of treating patients with CAP and concomitant alcoholic LC Child-Pugh Class A and 
B. 
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